CABAZITAXEL DR.REDDY'S cabazitaxel 60 mg/1.5 mL concentrated injection vial

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

cabazitaxel, Quantity: 60 mg

Available from:

Dr Reddys Laboratories Australia Pty Ltd

Pharmaceutical form:

Injection, concentrated

Composition:

Excipient Ingredients: polysorbate 80; citric acid

Administration route:

Intravenous Infusion

Units in package:

1

Prescription type:

(S4) Prescription Only Medicine

Therapeutic indications:

Cabazitaxel Dr.Reddy?s in combination with prednisone or prednisolone is indicated for the treatment of patients with metastatic castration resistant prostate cancer previously treated with a docetaxel containing regimen.

Product summary:

Visual Identification: Clear yellow to brownish-yellow viscous solution.; Container Type: Multiple containers; Container Material: Glass; Container Life Time: 36 Months; Container Temperature: Store below 30 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Authorization status:

Registered

Authorization date:

2018-07-23